Cypress Bioscience

Exagen will pay Cypress up to $8 million in upfront and milestone payments as well as additional royalty payments for the business.

Under the deal, Marina will receive $750,000 up front, and stands to be paid as much as $27 million in milestones.

The firm offers its Avise PG test as a service for physicians making decisions about methotrexate therapy.

Cypress will pay up to $5 million for the technology, which it plans to use for diagnosis and therapeutic monitoring of lupus patients.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.